NASDAQ$GPCR
Structure Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported second quarter 2024 financial results and recent highlights.
Structure Therapeutics reported its second quarter 2024 financial results, highlighting a strong cash position of $927.1 million, which is expected to fund operations through at least 2027. The company is advancing its GSBR-1290 program with a Phase 2b study expected to start in Q4 2024 and anticipates selecting a development candidate for its amylin program in the same quarter.
- GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024.
- Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024.
- Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors.
- Strong financial position with cash balance of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027.
Headline financials
Revenue & EPS history
Structure Therapeutics · Revenue · Quarterly
$0
Forward guidance
Structure Therapeutics is focused on advancing its GSBR-1290 program and expanding its pipeline of oral small molecule therapeutics for metabolic and cardiopulmonary diseases.
Tailwinds
- GSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter 2024.
- Oral small molecule amylin receptor agonist development candidate expected to be selected in fourth quarter of 2024.
- Obesity pipeline consists of four oral small molecule programs targeting GLP-1, GIP, amylin and APJ receptors.
- Strong financial position with cash balance of $927.1 million expected to fund projected operations and key clinical milestones through at least 2027.
- Advancing GSBR-1290 as rapidly as possible with the Phase 2b study expected to start before the end of the year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q2 2024
+1.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+9.8%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+14.8%
Q4 2024
Best reaction
-11.6%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | -2.5% | -29.1% | |
| Q3 2025 | -2.0% | +7.3% | +3.3% | |
| Q1 2025 | -4.6% | -11.2% | -21.2% | |
| Q4 2024 | +14.8% | +13.1% | -0.6% | |
| Q3 2024 | +1.9% | -14.1% | -15.5% | |
| Q2 2024 | -0.8% | +0.9% | +8.6% | |
| Q1 2024 | -8.7% | -9.0% | +35.3% | |
| Q4 2023 | -2.5% | -5.9% | +15.1% | |
| Q3 2022 | +11.5% | +7.1% | +23.4% | |
| Q3 2023 | -11.6% | -1.6% | +7.2% | |
| Q2 2023 | -1.9% | -2.9% | -0.1% | |
| Q2 2022 | -1.9% | -2.9% | -0.1% | |
| Q1 2023 | +8.9% | +1.9% | +40.2% | |
| Q4 2022 | +8.9% | +1.9% | +40.2% | |
| Q1 2022 | +8.9% | +1.9% | +40.2% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro